An Ebola whole-virus vaccine is protective in nonhuman primates

Science

Volumn 348, Issue 6233, 2015, Pages 439-442

  Marzi, Andrea ^a   Halfmann, Peter ^b   Hill Batorski, Lindsay ^b   Feldmann, Friederike ^a   Shupert, W Lesley ^a   Neumann, Gabriele ^b   Feldmann, Heinz ^a   Kawaoka, Yoshihiro ^b,c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c International Research Center for Infectious Diseases   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; HYDROGEN PEROXIDE; INACTIVATED VACCINE; VIRUS RNA; LIVE VACCINE; VIRUS PROTEIN;

DISEASE INCIDENCE; HYDROGEN PEROXIDE; IMMUNE SYSTEM; INFECTIVITY; PIG; POPULATION OUTBREAK; PRIMATE; PROTEIN; RNA; RODENT; VACCINE; VIRAL DISEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; MACACA FASCICULARIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTECTION; ZAIRE EBOLAVIRUS; ANIMAL; DRUG EFFECTS; EBOLAVIRUS; GAMMA RADIATION; GUINEA PIG; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MOUSE; RADIATION RESPONSE; VIRUS REPLICATION;

WEST AFRICA;

CAVIA; EBOLA VIRUS; MUS; PRIMATES; RODENTIA; ZAIRE EBOLAVIRUS;

ANIMALS; EBOLA VACCINES; EBOLAVIRUS; GAMMA RAYS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HYDROGEN PEROXIDE; MACACA FASCICULARIS; MICE; RNA, VIRAL; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84928383358     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaa4919     Document Type: Article

References (29)

1. www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html
2. A. Marzi, H. Feldmann, Expert Rev. Vaccines 13, 521-531 (2014).
3. U. N. Sarwar et al., J. Infect. Dis. 211, 549-557 (2015).
4. J. E. Martin et al., Clin. Vaccine Immunol. 13, 1267-1277 (2006).
5. www.niaid.nih.gov/news/newsreleases/2014/Pages/EbolaVaxCandidate.aspx.
6. N. J. Sullivan, A. Sanchez, P. E. Rollin, Z. Y. Yang, G. J. Nabel, Nature 408, 605-609 (2000).
7. N. J. Sullivan et al., Nat. Med. 17, 1128-1131 (2011).
8. D. A. Stanley et al., Nat. Med. 20, 1126-1129 (2014).
9. T. W. Geisbert et al., J. Virol. 83, 7296-7304 (2009).
10. T. W. Geisbert et al., Vaccine 26, 6894-6900 (2008).
11. S. M. Jones et al., Nat. Med. 11, 786-790 (2005).
12. X. Qiu et al., PLOS ONE 4, e5547 (2009).
13. I. J. Amanna, M. K. Slifka, Antiviral Res. 84, 119-130 (2009).
14. T. W. Geisbert et al., Emerg. Infect. Dis. 8, 503-507 (2002).
15. P. Halfmann et al., Proc. Natl. Acad. Sci. U.S.A. 105, 1129-1133 (2008).
16. P. Halfmann et al., J. Virol. 83, 3810-3815 (2009).
17. I. J. Amanna, H. P. Raué, M. K. Slifka, Nat. Med. 18, 974-979 (2012).
18. J. M. Walker, H. P. Raué, M. K. Slifka, J. Virol. 86, 13735-13744 (2012).
19. A. K. Pinto et al., J. Virol. 87, 1926-1936 (2013).
20. J. L. Dembinski et al., J. Virol. Methods 207, 232-237 (2014).
21. D. L. Brining et al., Comp. Med. 60, 389-395 (2010).
22. A. Marzi et al., Proc. Natl. Acad. Sci. U.S.A. 110, 1893-1898 (2013).
23. J. E. Blaney et al., PLOS Pathog. 9, e1003389 (2013).
24. K. L. Warfield et al., J. Infect. Dis. 196 (suppl. 2), S430-S437 (2007).
25. A. Takada et al., J. Virol. 77, 1069-1074 (2003).
26. K. L. Warfield et al., J. Infect. Dis. 196 (suppl. 2), S421-S429 (2007).
27. D. L. Swenson et al., Vaccine 23, 3033-3042 (2005).
28. K. L. Warfield et al., J. Immunol. 175, 1184-1191 (2005).
29. E. S. Kempner, J. Pharm. Sci. 90, 1637-1646 (2001).